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The spectacular improvement in long-term prognosis
of patients with hematological malignancies since the
1980s, coupled with the subsequent improvement
over the past decade in short- and mid-term survival
in cases of critical illness, resulted in an increasing
referral of such patients to the ICU. A remaining
question, however, is how these patients perform in
the long term with regard to survival and quality of
life. Here we discuss the present multicenter study on
survival beyond 1 year in critically ill patients with
hematological malignancies. We conclude with
suggestions on how we can further improve the
long-term outcome of these patients.1.5 years if only one of these factors was present. Of note,The long-term survival of patients with hematological
malignancies has improved dramatically over the past
decades. Nowadays, about 40% of patients with acute
leukemia or high-grade non-Hodgkin lymphoma survive
for more than 5 years and about 30% of these patients
can be cured. Unfortunately, owing to their underlying
disease or treatment or both, these patients are at high
risk of severe complications, often requiring transfer to
the ICU. Historically, intensivists have been reluctant to
admit these patients to the ICU because of the almost
uniformly fatal prognosis reported in the literature in
patients with evolving organ dysfunction requiring
mechanical ventilation, vasopressors, or renal replace-
ment therapy alone or in combination. Over the past
decade, several centers around the world that specialize
in the management of these patients have clearly shown
that these grim prognostic estimates no longer hold and
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© BioMed Central Ltd.2014simply because of their underlying malignancy, is no
longer justified. This has resulted in an increasing refer-
ral of such patients to the ICU. An important remaining
question, however, is how these patients perform in the
long term with regard to survival and quality of life.
In a study in the previous issue of Critical Care, Bernal
and colleagues [1] focused on the determinants of survival
beyond 1 year in a multicenter setting. As could be ex-
pected from what we observed at the bedside, functional
status (Eastern Cooperative Oncology Group performance
status of more than 2), relapsing hematological malig-
nancy, and absence of compliance with the scheduled
therapy for the underlying disease after ICU discharge
were associated with a worse survival. However, what was
less expected is that the survival reached nearly 0% after
only 62 patients were included in this study, and depen-
ding on whether we focus on a half-empty or half-full
glass, the other half of the patients achieved a 5-year
post-ICU survival of 40% to 50%. In the largest study ever
published, including more than 1,000 patients with
hematological malignancies admitted over a 16-month
period in 17 specialized centers in France and Belgium,
hospital survival was 60.7%; up to 80% of these patients
had no change in treatment intensity, and 80% were in
complete or partial remission 6 months after ICU
discharge [2]. Moreover, recent studies have shown that
ICU admission does not influence long-term outcome in
patients with acute myeloid leukemia who survive the first
30 days after ICU discharge: they had similar survival and
complete remission rates up to 3 years [3] and 6 years [4],
respectively, after discharge in comparison with acute
myeloid leukemia patients for whom ICU admission was
not necessary. Therefore, what the study by Bernal and
colleagues [1] shows above all is that being technically
skilled in advanced life-support therapies is not enough to
improve long-term outcome; as intensivists, we also have
to acknowledge better when to use these therapies and
when we have to withdraw them during ICU stay [5].
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survival and quality of life should be taken into account
upon referral to the ICU [5,6]. Only close collaboration
and in-depth communication between hematologists and
intensivists upon referral and during ICU stay can bridge
the two extremes of the overoptimistic oncologists who
often overestimate the long-term survival of their patients
in daily practice [7,8] and the overpessimistic intensivists
who are reluctant to admit them. Such an open and
constructive atmosphere, in which physicians assume a
leading role, disseminate a clear vision, and let other team
members, the patients, and relatives actively and safely
participate in the decision-making processes [9,10], will
not only improve the average long-term outcome of
published series focusing on any severe underlying
comorbidity but also reduce the burden for individual
patients and their relatives at the bedside [5,11]. Health-
care workers will also benefit, since real or perceived
disproportional care in the ICU leads to acute or, much
worse, more subtle chronic conflicts within the team,
resulting in poor quality of care [5,9,10,12]. The latter is
particularly deleterious since it will affect the patient’s
short- and long-term outcome in general, regardless of
whether the admission is justified or not.Conclusions
A good admission policy is necessary in order to safeguard
the quality of ICU care provided to patients with good
long-term expectations on the one hand and to reduce the
burden for patients and relatives with poor long-term
expectations on the other. This can be achieved only by
creating working environments enhancing close colla-
boration and communication between intensivists and
hematologists and where the patient and relatives are
closely involved in the decision-making process upon ICU
referral and during ICU stay. It is important to note that
this holds not only for patients with hematological malig-
nancies such as in the study by Bernal and colleagues [1]
but also for patients with any other severe underlying
comorbidity that are increasingly referred to the ICU.Competing interests
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